XTL Biopharmaceuticals Ltd. - ADR
$2.53
$0.03
(1.20%)
As on 04-Sep-2026 13:21EDT
Market cap
$6 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
1.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
16.9
-
Debt to Equity
-1.1
-
Book Value
$--
-
EPS
$-15.8
-
Face value
--
-
Shares outstanding
2,457,463
10 Years Aggregate
CFO
$-12.42 Mln
EBITDA
$-13.48 Mln
Net Profit
$-9.48 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
XTL Biopharmaceuticals - ADR
| 9.1 | -11.6 | 11.9 | -86.6 | -45.4 | -49.3 | -29.2 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
XTL Biopharmaceuticals - ADR
| -92.8 | 99.4 | -16.5 | -56.3 | -8.6 | 121.2 | -20.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
XTL Biopharmaceuticals - ADR
|
2.5 | 6.1 | 0.0 | -7.0 | -183.8 | -269 | -- | 1.9 |
| 13.5 | 850.9 | 0.0 | -175.9 | -- | -106.8 | -- | 5.7 | |
| 28.0 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 14.1 | 2,151.8 | 549.1 | 17.9 | -6.3 | 1.4 | 123.8 | 1.7 | |
| 17.3 | 2,261.9 | 120.3 | -57.5 | -108.2 | -9.9 | -- | 4.1 | |
| 11.3 | 828.1 | 366.5 | 9.3 | 8.3 | 3.4 | 83.6 | 3.1 | |
| 3.7 | 654.8 | 4.1 | -187.9 | -4,613.1 | -233.9 | -- | 0.3 | |
| 14.7 | 834.1 | 0.6 | -60.0 | -9,892.6 | -119 | -- | 21.8 | |
| 6.9 | 609.7 | 143.5 | -158.2 | -80.2 | -168.9 | -- | 6.6 | |
| 26.1 | 2,927.9 | 449.6 | -188.2 | -41.1 | -28.5 | -- | 5.0 |
Shareholding Pattern
View DetailsAbout XTL Biopharmaceuticals - ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready... asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel. Read more
-
CEO & Director
Mr. Shlomo Spokone Shalev
-
CEO & Director
Mr. Shlomo Spokone Shalev
-
Headquarters
Herzliya
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for XTL Biopharmaceuticals - ADR
What is the current share price of XTL Biopharmaceuticals Ltd - ADR Today?
The share price of XTL Biopharmaceuticals Ltd - ADR is $2.53 (NASDAQ) as of 04-Sep-2026 13:21 EDT. XTL Biopharmaceuticals Ltd - ADR has given a return of -45.44% in the last 3 years.
What is the current PB & PE ratio of XTL Biopharmaceuticals Ltd - ADR?
Since, TTM earnings of XTL Biopharmaceuticals Ltd - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.04 |
-1.00 |
2024 |
-1,738.57 |
328.52 |
2023 |
-3,088.43 |
2.48 |
2022 |
-0.31 |
0.10 |
2021 |
2.29 |
0.19 |
What is the 52 Week High and Low of XTL Biopharmaceuticals Ltd - ADR?
The 52-week high and low of XTL Biopharmaceuticals Ltd - ADR are Rs 52.29 and Rs 2.02 as of 05-Sep-2026.
What is the market cap of XTL Biopharmaceuticals Ltd - ADR?
XTL Biopharmaceuticals Ltd - ADR has a market capitalisation of $ 6 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in XTL Biopharmaceuticals Ltd - ADR?
Before investing in XTL Biopharmaceuticals Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.